CGC / Another quarter, another loss for Canopy Growth — and ‘misstatements' in BioSteel sales

Canopy Growth's hopes hinge on federal marijuana legalization in the U.S. Federal legalization could still be years away, and there's no guarantee tha more_horizontal

In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business. more_horizontal

Investors and traders in the Canadian cannabis market are closely monitoring the leading Canadian cannabis stocks as November draws near. Recent years more_horizontal

The current activity in the U.S. House of Representatives doesn't benefit cannabis companies. While the chamber lacks a Speaker, it can't conduct any more_horizontal

As we enter the fourth quarter of 2023 the cannabis sector is progressing into the future. More companies are working on various ventures and developi more_horizontal

Cannabis stocks have been stagnant or declining due to cash burn and regulatory challenges. Despite this, many bulls have once again begun expecting a more_horizontal

Canopy Growth's cash burn is high but could improve as the company stops funding BioSteel. Dilution, however, may become a much bigger problem for inv more_horizontal

Pity the average cannabis stock investor. Since 2021, shares of the largest cannabis fund, the AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS ) ha more_horizontal